Hualan Biological Engineering Inc. (SHE: 002007)

Market Cap	27.07B
Revenue (ttm)	5.41B
Net Income (ttm)	1.40B
Shares Out	1.83B
EPS (ttm)	0.76
PE Ratio	19.41
Forward PE	17.83
Dividend	0.30 (2.01%)
Ex-Dividend Date	Jun 14, 2024

Volume	2,860,948
Open	15.23
Previous Close	14.94
Day's Range	14.81 - 15.23
52-Week Range	14.46 - 24.55
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Hualan Biological Engineering

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 3,709
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2023, Hualan Biological Engineering's revenue was 5.34 billion, an increase of 18.26% compared to the previous year's 4.52 billion. Earnings were 1.48 billion, an increase of 37.66%.